UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-41173 WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 OR NexGel, Inc. (Exact name of registrant as specified in its charter) | Delaware | 26-4042544 | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-36278 NexGel, Inc. (Exact name of registrant as specified in its charter) Delaware 26-4042544 (State or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-36278 NexGel, Inc. (Exact name of registrant as specified in its charter) Delaware 26 ...

Table of Contents | UNITED STATES | | | | --- | --- | --- | | SECURITIES AND EXCHANGE COMMISSION | | | | WASHINGTON D.C. 20549 | FORM 10-K | | | (Mark One) | | | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the fiscal year ended: December 31, 2021 | | | | OR | | | | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | ☐ | | For the transition period from ___________ to ___________ | | | | Commission file number: ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-36278 NexGel, Inc. (Exact name of registrant as specified in its charter) Delawar ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-36278 NexGel, Inc. (Exact name of registrant as specified in its charter) Delaware 26- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-36278 NexGel, Inc. (Exact name of registrant as specified in its charter) | Delaware | 26-4042544 | | - ...

Revenue Concentration - The company reported that three major customers accounted for approximately 78% of its revenue for the year ended December 31, 2020, with individual contributions of 45%, 22%, and 11% respectively[20] - The company has been supplying its major customers for over fifteen years and does not anticipate any change in their intentions to use its services[20] Business Strategy - The company is implementing a new strategy to transition into a consumer products business focused on proprietary branded products and white label opportunities[14] - The company has historically served as a contract manufacturer, supplying gels to third parties who incorporate them into their own products[14] Research and Development - The company did not incur any research and development costs for the years ended December 31, 2020, and 2019, and plans to commit resources to R&D only as cash resources allow[30] - The company has not incurred any research and development costs for the years ended December 31, 2020, and 2019, and plans to commit resources to R&D only as cash resources allow[30] Employee and Operations - As of December 31, 2020, the company had eight full-time employees, with five involved in manufacturing and regulatory matters[32] - The company currently has eight full-time employees, with five involved in manufacturing and regulatory matters[32] Product and Market Focus - The company specializes in high water content, electron beam cross-linked, aqueous polymer hydrogels used for various applications including wound care and drug delivery[14] - The company’s hydrogels are marketed for applications including drug delivery, moist wound dressings, and cosmetic uses[15] - The company’s hydrogels are marketed for various applications, including drug delivery, wound care, and cosmetic uses[15] Intellectual Property - The company holds patent rights to one patent in Europe, which is set to expire in September 2021, and has exclusive licenses for two issued patents related to transdermal patches[21] - The company has a patent in Europe covering the use of lignin for inhibiting restenosis and thrombosis formation, which is set to expire in September 2021[21] Supply Chain - The company relies on several principal suppliers for raw materials, including Berry Global, Inc., DeWolf Chemical, Inc., and Univar Inc.[17] Regulatory Compliance - The company is currently registered as a device manufacturer and human tissue distributor with the FDA and intends to register as a drug facility when required[26] - The company is currently registered as a device manufacturer and human tissue distributor with the FDA and intends to register as a drug facility when required[26] Inventory Management - The company maintains sufficient inventory of components to avoid significant production disruptions[17]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-36278 NexGel, Inc. (Exact name of registrant as specified in its charter) Delaware 26-4042544 (Stat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered pursuant to Section 12(b) of the Act: None. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such repo ...